JFL Life Sciences Limited IPO: Details, Review, Allotment date and Subscription Status
jfl life sciences limited ipo Review, allotment date, subscription and grey market premium(gmp)
Incorporated in 2010, JFL Life Sciences Limited is engaged in the business of manufacturing of pharmaceutical
products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam)
solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS).
The company's sales strategy is to sell the products in bulk to pharmaceutical marketers and traders who in turn provide
the channel for sales to customers. JFL Life Sciences Limited has a market presence in PAN India and JFL's products
are supplied to 10 developed and developing countries throughout the World. JFL Life Sciences Limited exports products to African, Middle Eastern, and CIS countries, mainly through merchant exporters. The company is registered with
the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing a particular product. Few of our products
are also registered with Ukraine, Uzbekistan, and Kazakhstan (CIS countries) through merchants.
jfl life sciences limited ipo, jfl life sciences limited ipo details, jfl life sciences limited ipo time table, jfl life sciences limited ipo gmp, jfl life sciences limited ipo grey market premium, jfl life sciences limited ipo subscription, jfl life sciences limited ipo allotment status, jfl life sciences limited ipo allotment link
>Disclaimer: Stock Market investments are subject to market risks, read
all scheme related documents carefully before investing. All the information provided on our
IPO Portal is for Reaserch purpose only. I do not claim any facts, and figure mentioned
here. Source: SmartInvestment
JFL Life Sciences Limited IPO Review
Issue Opens on 25nd August & Closes on 30th August 2022
Object of the issue : Repayment of secured and unsecured loans,
Funding the working capital requirements of the company and General Corporate Purposes
Company Management : Smiral Ashwinkumar Patel, Tejal Smiral Patel
Market Cap : Rs. 67.09 Cr.
Pre Issue Promoter Holding : 92.52%
Post Issue Promoter holding : 62%
Issue constitutes 27.08% of the post issue paid up capital
Average of last 3 Yrs. EPS Rs. 0.76& RONW : 7.18%
Pre IPO Eq. Capital Rs. : 8.02 Cr.
Post IPO Eq. Capital Rs.11 Cr.
Pre IPO : P/BV Ratio 4.46 (NAV : 13.67)
Post Issue : P/BV Ratio : 2.30 (NAV : 26.48)
Post IPO asking P/E on fully diluted equity : 26.52
BRLM’s Performance : This is 6th Issue from BRLM in last 2 years. In last 4 Listing : 4 Issued opened with premium
& 2 Issue Discount.
OTHER SIDE OF THE COIN
The average cost of acquisition of equity shares by the promoter is Rs. 9 and Rs. 9.31 per share and offer price is Rs.
61 per share.
It has issued bonus shares in the ratio of 12:1 in January 2022 before filing DRHP
Apart from initial equity capital at par, the company issued further equity shares at the price range of Rs. 91 to 130
before march 2013 and January 2021
On financial front revenue almost remained static from 2019 to 2021 and down in 2022. However with lower revenue
in 2022 profit has incurred five times.
It depends on few customers. Top 10 customers contributed 91.5% revenue.
It requires significant amount of working capital.
Company operated in competitive business environment
Recommendation : It has posted static revenue from 2019 to 2021 and down in 2022. However
reported consistent growth in bottom lines from 2019 to 11MFY22. On valuation front issue is fully
priced but considering expansion attractive margins, fancy in pharma segment, investors may apply for long term prospectiv
Post a Comment